Certara (CERT) investor relations material

Executive summary

• Q2 2026 revenue grew 1% year-over-year to $93.3 million, with software up 4% and services down 3%.

• Net loss from continuing operations was $6.1 million, compared to net income of $1.5 million in Q2 2025, mainly due to higher operating expenses and non-recurring items.

• Adjusted EBITDA was $26.2 million (28% margin), down from $27.0 million in Q2 2025; adjusted net income was $12.5 million, nearly flat year-over-year.

• Completed divestiture of the Regulatory and Medical Writing business in May 2026, sharpening focus on core strengths and resulting in a $49.2 million loss from discontinued operations.

• Strategic actions included a reduction in force impacting 5% of employees (targeting $13 million in annual savings), reorganization into two business units, and leadership changes.

Financial highlights

• Q2 2026 total revenue was $93.3 million (+1% YoY); software revenue $48.8 million (+4% YoY), services revenue $44.5 million (-3% YoY).

• Total bookings for Q2 2026 were $98.3 million (+1% YoY); software bookings $50.7 million (+9% YoY), services bookings $47.6 million (-6% YoY).

• Adjusted EBITDA margin for Q2 2026 was 28%.

• Adjusted diluted EPS was $0.08, flat year-over-year.

• Cash and cash equivalents at quarter-end were $184.1 million.

Outlook and guidance

• Full-year 2026 revenue guidance reaffirmed at $367 million to $382 million (0%–4% growth).

• Software revenue expected at or above the high end of the range; services at or below the low end.

• Adjusted EBITDA margin guidance revised to 29%–31%.

• Full-year adjusted diluted EPS expected between $0.31 and $0.36.

• Fully diluted shares projected at 155–157 million.